地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗乳腺癌化疗后粒细胞减少价值研究  

Study on Reduction Value of Granulocytes in Treatment of Breast Cancer Chemotherapeutic Cells by Combination of Polyethylene Glycol Recombinant Human Granulocyte Stimulating Factor

作　　者：张敏[1] 帅晋豪[1] ZHANG Min;SHUAI Jinhao(Department of General Surgery, Meishan People's Hospital, Meishan 620010 , Sichuan, China)

机构地区：[1]眉山市人民医院普外科,四川眉山620010

出　　处：《中华中医药学刊》2019年第5期1201-1204,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：四川省卫生厅基金项目(150075);眉山市科技计划项目(2016666)

摘　　要：目的:探究地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗乳腺癌化疗后粒细胞减少价值。方法:114例乳腺癌化疗后粒细胞减少患者,采取随机数字表法平均分为观察组以及对照组,对照组所有患者(57例)均采取聚乙二醇化重组人粒细胞刺激因子治疗,观察组所有患者(57例)则采取地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗,对比两组患者临床治疗效果、治疗前后患者症状积分、患者发热持续时间及粒细胞缺乏持续时间、治疗过程中不良反应情况及患者对治疗满意程度。结果:观察组患者治疗总有效率(98.25%)高于对照组(87.72%),P<0.05,差异具有统计学意义;观察组患者治疗前症状积分为(7.45±1.04)分,对照组症状积分为(7.43±1.11)分,两组患者治疗前症状积分相当,P>0.05,差异无统计学意义,治疗后观察组积分为(2.33±0.46)分,对照组积分为(3.89±0.48)分,经治疗后各组患者症状积分均一定程度下降,患者症状均改善,观察组改善优于对照组,P<0.05,差异具有统计学意义;观察组患者治疗后发热持续时间为(6.34±1.32)d,短于对照组(10.24±1.11)d,粒细胞缺乏持续时间为(5.11±1.01)d,短于对照组(8.42±1.06)d,P<0.05,差异具有统计学意义;观察组治疗过程中总不良反应发生率(1.75%)与对照组(3.51%)相当,两组不良反应发生率均较低,P>0.05,差异无统计学意义;观察组患者治疗总满意率(96.49%)高于对照组(85.96%),P<0.05,差异具有统计学意义。结论:地榆升白片联合聚乙二醇化重组人粒细胞刺激因子治疗乳腺癌化疗后粒细胞减少效果良好,患者粒细胞减少症状明显改善,且患者恢复快,满意率高,值得临床广泛推广以及应用。Objective:To explore the value of granulocytes in the treatment of breast cancer chemoradiotherapy by using the combination of Diyu Shengbai Tablets and polyethylene glycol recombinant human granulocyte stimulating factor.Methods:114 cases of breast cancer after chemotherapy granulocytopenia patients as the research objects, according to a random number table method,were divided into observation group and control group. The control group’s patients(57 cases) were treated with polyethylene glycol and recombinant human granulocyte stimulating factor. The observation group’s patients(57 cases) tookDiyu Shengbai Tablets combined with polyethylene glycol recombinant human granulocyte stimulating factor treatment. We compared two groups’ clinical therapeutic effect, duration of symptoms integral before and after treatment, patients fever and granulocyte lack of duration, treatment process and adverse reaction.Results:The total effective rate(98.25%) in the observation group was higher than that in the control group(87.72%)(P<0.05) and the difference was statistically significant. Observation group’s symptoms integral was(7.45±1.04) points and the control group’swas(7.43±1.11) points. Two groups’ symptoms integral before treatment had no statistically significant(P>0.05). The observation group’s after treatmentsymptoms integral was(2.33±0.46) points and the control group’s was(3.89±0.48) points after treatment. After treatment both groups’ symptoms integral decreased to a certain degree and patients’ symptoms were improved. The observation group’s improvementwas better than that of the control group(P<0.05) and the difference was statistically significant. The observation group’s fever duration(6.34±1.32)d was shorter than the control group’s(10.24±1.11)d and granulocyte lack duration(5.11±1.01)d was shorter than the control group’s(8.42±1.06)d after treatment(P<0.05) and the difference was statistically significant. The incidence of total adverse reactions(1.75%) was similar to that

关 键 词：乳腺癌 化疗 粒细胞减少 地榆升白片 聚乙二醇化重组人粒细胞刺激因子 

分 类 号：R737.9[医药卫生—肿瘤]